Home >> Signaling Pathways >> JAK/STAT Signaling

JAK/STAT Signaling(JAK/STAT 信号通路)

Products for  JAK/STAT Signaling

  1. Cat.No. 产品名称 Information
  2. GC25992 TG-89 TG-89 is an inhibitor of JAK2 with IC50 of 11.2 μM.
  3. GC25899 SC-1 SC-1 (1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea, STAT3-IN-7), a Sorafenib analogue and potently inhibits the phosphorylation of STAT3, induces cell apoptosis through SHP-1 dependent STAT3 inactivation.
  4. GC25869 RO495 RO495 (CS-2667) is a potent inhibitor of Non-receptor tyrosine-protein kinase 2 (TYK2).
  5. GC25559 Lapatinib (GW-572016) Ditosylate Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
  6. GC25219 CH7233163 CH7233163 is a non-covalent ATP competitive inhibitor of EGFR-tyrosine kinase with antitumor activities against tumor with EGFR-Del19/T790M/C797S.
  7. GC25168 Brepocitinib (PF-06700841) Brepocitinib (PF-06700841, PF-841) is a potent inhibitor of Tyk2 and Jak1 with IC50s of 23 nM, 17 nM, 77 nM for Tyk2, Jak1 and Jak2 respectively. It has appropriate in-family selectivity against JAK2 and JAK3.
  8. GC67958 HP590
  9. GC67867 VVD-118313
  10. GC67860 JBJ-09-063 TFA
  11. GC67779 STX-0119
  12. GC67759 Lapatinib-d4
  13. GC67749 Amivantamab
  14. GC67706 LY5
  15. GC67690 JBJ-09-063 hydrochloride
  16. GC52293 STAT3 Inhibitor 4m A STAT3 inhibitor
  17. GC66432 EAI001
  18. GC66428 EGFR-IN-5
  19. GC66405 Panitumumab Panitumumab (anti-EGFR, ABX-EGF) is a recombinant, fully human IgG2 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR).
  20. GC66333 Panitumumab (anti-EGFR)
  21. GC66329 NDI-034858
  22. GC65992 FGFR2-IN-3
  23. GC65991 FGFR2-IN-3 hydrochloride
  24. GC65974 EGFR-IN-9
  25. GC65572 EGFR Protein Tyrosine Kinase Substrate
  26. GC65453 JAK-IN-3
  27. GC65436 JND3229 JND3229 is a potent reversible inhibitor of EGFRC797S with an IC50 value of 5.8 nM. JND3229 also potently suppresses EGFRL858R/T790M and EGFRWT with IC50 values of 30.5 nM and 6.8 nM, respectively.
  28. GC65405 JAK2-IN-6
  29. GC65387 Tyk2-IN-5
  30. GC65344 STAT5-IN-2 STAT5-IN-2 inhibits the growth of acute and chronic myeloid leukemia cells and the phosphorylation and transcriptional activity of STAT5, but not STAT3, AKT, or Erk1/2 phosphorylation, with minimal effects on bone marrow stromal cells that play vital functions in the microenvironment of hematopoietic and leukemic cells.
  31. GC65310 TAS0728 A covalent HER2 inhibitor
  32. GC65278 PIM1-IN-1
  33. GC65201 Quercetagetin A selective Pim-1 inhibitor
  34. GC65020 Danvatirsen
  35. GC64959 JAK/HDAC-IN-1
  36. GC64891 YM-341619
  37. GC64774 SEL24-B489
  38. GC64770 Oritinib
  39. GC64710 MC-Val-Cit-PAB-Amide-TLR7 agonist 4
  40. GC64701 Povorcitinib
  41. GC64700 Povorcitinib phosphate
  42. GC64497 EGFR-IN-17
  43. GC64398 Almonertinib mesylate
  44. GC64372 Lorpucitinib
  45. GC64302 BAY 2476568
  46. GC64108 Ifidancitinib
  47. GC64039 Disitamab vedotin
  48. GC64017 Befotertinib
  49. GC63910 BLU-945 BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC).
  50. GC63864 (E/Z)-Zotiraciclib hydrochloride
  51. GC63797 (S)-Sunvozertinib DZD9008 (Sunvozertinib) is an oral, potent, irreversible, wild type-selective EGFR inhibitor against EGFR or HER2 Exon20ins and other mutations with IC50 ranging from 0.4 nM to 2.1 nM for mutant EGFR.

Items 1 to 50 of 417 total

per page
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction